56913-08-7

Basic information

• Product Name: 2-(4-chloro-2-methoxyphenoxy)acetic acid
• Synonyms: 2-(4-chloro-2-methoxyphenoxy)acetic acid
• CAS NO: 56913-08-7
• Molecular Formula: C₉H₉ClO₄
• Molecular Weight: 216.61836
• Mol File: 56913-08-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(4-chloro-2-methoxyphenoxy)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-chloro-2-methoxyphenoxy)acetic acid(56913-08-7)
• EPA Substance Registry System: 2-(4-chloro-2-methoxyphenoxy)acetic acid(56913-08-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 56913-08-7(Hazardous Substances Data)

Usage

Uses

Used in Agricultural Industry:
2-(4-chloro-2-methoxyphenoxy)acetic acid is used as a post-emergent herbicide for the control of broadleaf weeds in various crops. It is applied either as a spray or in granular form to effectively manage and eliminate unwanted weeds such as common chickweed, field pansy, and shepherd's purse, thereby improving crop yield and quality by reducing competition for resources and preventing crop damage.
If additional applications or industries are mentioned in the provided materials, they would be listed here with the corresponding application type and reason. However, based on the current information, the primary use of 2-(4-chloro-2-methoxyphenoxy)acetic acid is within the agricultural industry for weed control.

Upstream product

• 16766-30-6 4-Chloroguaiacol 
• 3251-56-7 2-methoxy-4-nitrophenol 
• 937817-42-0 (4-chloro-2-methoxyphenoxy)acetic acid tert-butyl ester 
• 79-11-8 chloroacetic acid 

Downstream Products

• 7678-24-2 (4-Chloro-2-methoxy-phenoxy)-acetyl chloride 
• 7417-89-2 4-chloro-2-hydroxy phenoxyacetic acid 

Relevant articles and documents

INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY

The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.

Design, synthesis, and biological and crystallographic evaluation of novel inhibitors of plasmodium falciparum enoyl-ACP-reductase (pf fabi)

Malaria, a disease of worldwide significance, is responsible for over one million deaths annually. The liver-stage of Plasmodium's life cycle is the first, obligatory, but clinically silent step in malaria infection. The P. falciparum type II fatty acid biosynthesis pathway (PfFAS-II) has been found to be essential for complete liver-stage development and has been regarded as a potential antimalarial target for the development of drugs for malaria prophylaxis and liver-stage eradication. In this paper, new coumarin-based triclosan analogues are reported and their biological profile is explored in terms of inhibitory potency against enzymes of the PfFAS-II pathway. Among the tested compounds, 7 and 8 showed the highest inhibitory potency against Pf enoyl-ACP-reductase (PfFabI), followed by 15 and 3. Finally, we determined the crystal structures of compounds 7 and 11 in complex with PfFabI to identify their mode of binding and to confirm outcomes of docking simulations.

Identification of anthranilic acid derivatives as a novel class of allosteric inhibitors of hepatitis C NS5B polymerase

A series of potent anthranilic acid-based inhibitors of the hepatitis C NS5B polymerase has been identified. The inhibitors bind to a site on NS5B between the thumb and palm regions adjacent to the active site as determined by X-ray crystallography of the enzyme-inhibitor complex. Guided by both molecular modeling and traditional SAR, the enzyme activity of the initial hit was improved by approximately 100-fold, yielding a series of potent and selective NS5B inhibitors with IC50 values as low as 10 nM. These compounds were also inhibitors of the HCV replicon in cultured HUH7 cells.

Methods of using piperazine derivatives

The present invention relates to compounds of the formula I and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c, d, R1, R2, R3, R4 and R5 are as defined herein. Moreover, the present invention is also directed at pharmaceutical compositions comprising a compound of the formula I and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compounds and compositions for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal.